Patents Assigned to University of Wales
-
Patent number: 9017936Abstract: Methods and kits for identifying candidate anti-megakaryocyte agents are disclosed.Type: GrantFiled: October 5, 2010Date of Patent: April 28, 2015Assignees: Shire Human Genetic Therapies, Inc., University of Wales Institute, CardiffInventors: Jorge D. Erusalimsky, Maninder Ahluwalia
-
Patent number: 8383126Abstract: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described.Type: GrantFiled: October 29, 2007Date of Patent: February 26, 2013Assignee: University of Wales, AberstwythInventors: Galina V. Mukamolova, Arseny S. Kaprelyants, Danielle I. Young, Douglas B. Kell, Michael Young
-
Publication number: 20090120809Abstract: This invention provides a sensing device comprising an electrode comprising a noble metal layer, on which layer is located a biological material having nitroreductase activity. This invention further provides a method of detecting nitro group containing compounds, the method comprising the steps of: (a) providing a sensing device of the first aspect of the invention and a reference electrode; (b) applying a potential between the electrodes; (c) measuring the current; (d) contacting the sensing device with a sample of substrate material to be tested; and (e) measuring the current change.Type: ApplicationFiled: November 17, 2004Publication date: May 14, 2009Applicants: UNIVERSITY OF WALES, BANGOR, TRWYN LIMITEDInventors: Maher Kalaji, Peter Anthony Williams, Christopher David Gwenin
-
Publication number: 20090042289Abstract: The present invention relates to methods for preserving cells, in particular primary cells such as hepatocytes. In particular, the present invention relates to preserving cells within a gel comprising a hydrolysed gelatin and culturing the cells at a temperature between 0 and 15° C.Type: ApplicationFiled: September 5, 2008Publication date: February 12, 2009Applicants: University of Wales, Cardiff, ABCELLUTE LimitedInventors: Benjamin J. N. Griffiths, Peter John Evans
-
Patent number: 7462466Abstract: A graftable animal cell or tissue of a donor species for use in medicine expresses, or is capable of being caused to express, increased amounts of endogenous complement regulatory molecules for preventing activation of complement in a recipient species. Such tissue or organs are useful for xenotransplantation. Porcine complement regulatory proteins CD59, DAF have been sequenced. Also disclosed are methods of inducing in an animal cell or tissue resistance protection against complement attack.Type: GrantFiled: January 20, 2004Date of Patent: December 9, 2008Assignee: University of Wales College of MedicineInventors: Bryan Paul Morgan, Neil Kevin Rushmere, Stewart James Hinchliffe, Carmen Wilma Van Den Berg
-
Publication number: 20080206269Abstract: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described.Type: ApplicationFiled: October 29, 2007Publication date: August 28, 2008Applicant: The University of Wales, Aberyswyth Of Old CollegeInventors: Galina V. Mukamolova, Arseny S. Kaprelyants, Michael Young, Douglas B. Kell, Danielle I. Young
-
Patent number: 7405283Abstract: A screening method for identifying an individual having a pre-disposition towards having a cancer is disclosed, which screening method comprises the steps of: (a) obtaining a test sample comprising a nucleotide sequence comprised in a gene in a gene in a base excision repair (BER) pathway of the individual or an amino acid sequence of a polypeptide expressed thereby; and (b) comparing a region of the test sample sequence with the corresponding region of the wild type sequence, whereby a difference between the test sample sequence and the wild type sequence signifies that the individual is pre-disposed to having the cancer; and wherein the difference comprises a specified variation. The specified variation can be the known mutation in the human MYH protein, G382D-hMYH or a nucleotide sequence encoding it, or it can be one or more novel variations, namely, Y165C, E466X, and Y90X, or the respective corresponding nucleotide sequences.Type: GrantFiled: August 2, 2002Date of Patent: July 29, 2008Assignee: University of WalesInventors: Julian R. Sampson, Jeremy Peter Cheadle
-
Patent number: 7393940Abstract: A screening method for identifying an individual having a pre-disposition towards having a cancer is disclosed, which screening method comprises the steps of: (a) obtaining a test sample comprising a nucleotide sequence comprised in the MYH gene of the individual or an amino acid sequence of a polypeptide expressed thereby; and (b) comparing a region of the test sample sequence with the corresponding region of the wild type sequence, whereby a difference between the test sample sequence and the wild type sequence signifies that the individual is pre-disposed to having the cancer; and wherein the difference comprises a specified variation.Type: GrantFiled: October 11, 2005Date of Patent: July 1, 2008Assignee: University of WalesInventors: Julian R. Sampson, Jeremy P. Cheadle
-
Publication number: 20070172458Abstract: The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods for producing the fusion protein and the use of the fusion protein in the treatment of infectious diseases and inflammatory and immunological disorders.Type: ApplicationFiled: March 29, 2007Publication date: July 26, 2007Applicants: University College Cardiff Consultants Limited, University of Wales College of MedicineInventors: Simon Jones, Nicholas Topley
-
Patent number: 7052720Abstract: A mixture or substance having a spheroid-forming activity is obtained by heat treating fetal calf serum at a temperature and for a period sufficient to impart spheroid-forming activity. Introduced into cell culture, the substance or mixture so obtained causes cells to grow in three-dimensional cultures as opposed to mono-layer. Also disclosed are kits for the production of said mixture or substance and further uses of said mixture or substance.Type: GrantFiled: June 19, 2000Date of Patent: May 30, 2006Assignee: University of Wales College of MedicineInventor: Derek Leigh Jones
-
Publication number: 20060104964Abstract: An isolated, purified or recombinant nucleic acid sequence is disclosed, comprising: (a) a sequence that encodes both an angiogenic factor antagonist and a vascular endothelial structure regulator; (b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or (c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or (d) an oligonucleotide specific for any of the sequences (a), (b) or (c). Particular oligonucleotides (d) are those encoding the vascular endothelial structure regulator. Also described are methods for preparing the recombinant polynucleotide, proteins encoded by such polynucleotides and their use in gene or protein therapy for the treatment of conditions such as cancer.Type: ApplicationFiled: January 10, 2006Publication date: May 18, 2006Applicant: UNIVERSITY OF WALES COLLEGE OF MEDICINEInventor: Wen Jiang
-
Patent number: 7029564Abstract: In a dielectrophoretic cell having an array of electrodes and means to apply electrical signals to the electrodes. The electrodes include a planar array of serpentine or zig-zag electrodes with their curvatures in register. The serpentine electrodes may be sinusoidal, half sinusoidal, or elongated “C” in shape. The positions of maximum curvature of each serpentine or zig-zag electrode may be arranged in linear alignment, or along a curve. The cell may be used for stationary or traveling wave dielectrophoresis. Particles traveling in opposite directions in traveling wave dielectrophoresis can do so without interference, allowing “traffic control”. Particles can be characterized and separated, and particles at high concentrations, or particles of different types, can be handled.Type: GrantFiled: July 20, 2000Date of Patent: April 18, 2006Assignee: University of Wales, BangorInventors: Gary Lock, Ronald Pethig
-
Patent number: 6984520Abstract: An assay method for TSH-R autoantibodies or TSH comprises contacting a test sample, in the presence or absence of TSH, with cells from a clone expressing human TSH-R transfected with a reporter construct comprising cDNA of both (i) a reactant, such as an enzyme, capable of causing a measurable response when brought into contact with a corresponding substrate, such as a protein, and (ii) a promoter containing cyclic AMP (cAMP) response elements (CREs), whereby cAMP levels vary with expression of the reactant. Also disclosed are related kits, reporter constructs and related biological material.Type: GrantFiled: September 29, 1998Date of Patent: January 10, 2006Assignee: University of Wales College of MedicineInventor: Marian Elizabeth Ludgate
-
Patent number: 6945779Abstract: A tooth inclination apparatus for allowing assessment of the angle of inclination of an incisor tooth or cast thereof includes a plane element providing a flat datum surface for resting against e.g. the upper molars in the maxillary plane. From the underside of the plane element projects a protractor portion with a graduated angular scale which measures the angular deviation of an indicator pin pivoted to the plane member and moved to contact the tooth whose inclination is being measured. Other mechanical or electro-optic devices may be used to determine the inclination of the incisor relative to the datum surface.Type: GrantFiled: March 5, 2001Date of Patent: September 20, 2005Assignee: University of Wales College of MedicineInventor: Stephen Richmond
-
Patent number: 6936151Abstract: In a method of manipulating particles suspended in a liquid medium, a moving standing wave ultrasonic vibration and an electrical field capable of generating a dielectrophoretic force on the particles are applied. The ultrasonic vibration may be applied to move the particles from a first suspending liquid to a second suspending liquid, or to move the particles into proximity with electrodes to apply the dielectrophoretic force, or to move the particles into the center of the liquid medium. Alternatively, the ultrasonic vibration and the electrical field may be applied simultaneously.Type: GrantFiled: July 20, 2000Date of Patent: August 30, 2005Assignee: University of Wales, BangorInventors: Gary Lock, Ronald Pethig, Gerardus Hendricus Markx
-
Patent number: 6936618Abstract: The use of a type V cyclic nucleotide phosphodiesterase inhibitor for the preparation of a medicament for the treatment of cystic fibrosis.Type: GrantFiled: March 24, 2003Date of Patent: August 30, 2005Assignee: University of Wales College of MedicineInventors: Robert Leslie Dormer, Margaret Ann McPherson
-
Publication number: 20040163140Abstract: A graftable animal cell or tissue of a donor species for use in medicine expresses, or is capable of being caused to express, increased amounts of endogenous complement regulatory molecules for preventing activation of complement in a recipient species. Such tissue or organs are useful for xenotransplantation. Porcine complement regulatory proteins CD59, DAF have been sequenced. Also disclosed are methods of inducing in an animal cell or tissue resistance protection against complement attack.Type: ApplicationFiled: January 20, 2004Publication date: August 19, 2004Applicant: UNIVERSITY OF WALES COLLEGE OF MEDICINEInventors: Bryan Paul Morgan, Neil Kevin Rushmere, Stewart James Hinchliffe, Carmen Wilma Van Den Berg
-
Publication number: 20040137510Abstract: A detection method for detecting a variation in GH1 effective to act as an indicator of GH dysfunction in an individual, comprises the steps of comparing a test sample comprising a nucleotide sequence of the human GH1 gene from the individual with a standard sequence known to be that of the human GH1 gene. A difference between the test sample sequence and the standard sequence indicates the presence of a variation effective to act as an indicator of GH dysfunction (hereinafter “variant of GH1”).Type: ApplicationFiled: March 1, 2004Publication date: July 15, 2004Applicant: UNIVERSITY OF WALES COLLEGE OF MEDICINEInventors: David N. Cooper, Annie M. Procter, John Gregory, David S. Millar
-
Publication number: 20030229117Abstract: The use of a type V cyclic nucleotide phosphodiesterase inhibitor for the preparation of a medicament for the treatment of cystic fibrosis.Type: ApplicationFiled: March 24, 2003Publication date: December 11, 2003Applicant: UNIVERSITY OF WALES COLLEGE OF MEDICINEInventors: Robert Leslie Dormer, Margaret Ann McPherson
-
Patent number: 6599907Abstract: A method of treating cystic fibrosis in a patient comprising: administering to said patient an effective amount of a type V cyclic nucleotide phosphodisterase inhibitor, wherein said inhibitor is a compound of formula (I): wherein A is a five- or six-membered ring containing one or more N atoms, X is a substituent of formula (II): wherein R1 represents C1-4 alkyl, and X is positioned at either or both of the 2-position and/or the 8-position in (I).Type: GrantFiled: December 26, 2001Date of Patent: July 29, 2003Assignee: University of Wales College of MedicineInventors: Robert Leslie Dormer, Margaret Ann McPherson